Menu
Adoptive T cell therapy capitalizes on the body’s immune system to combat cancer by infusing ex vivo expanded T cells engineered to target cancerous cells. The process of large-scale expansion, particularly for therapies like CAR-T, is intricate and requires meticulous optimization to maximize T cell yield while preserving their desired function.
Optimal growth and viability are achieved through culturing immune cells with a high-quality activator supplemented with growth factors and immunomodulators in the growth medium, with a notable combination being Interleukin-7 (IL-7) and IL-15. These cytokines play pivotal roles as growth factors in ex vivo T cell expansion protocols, promoting rapid T cell multiplication and enhancing cytotoxicity, resulting in more potent cancer treatments.
Beyond their growth-promoting functions, IL-7 and IL-15 also fortify the survival and functionality of transferred T cells within the patient, ensuring a sustained assault on malignant cells.
Stem cell memory T cells (TSCM) benefit adoptive T cell therapy because they possess self-renewal and differentiation capabilities, ensuring prolonged persistence and potent anti-cancer effects, thereby enhancing the therapy’s longevity and effectiveness against cancer.
When supplemented with IL-7 and IL-15, T cells cultured using Nanotein’s innovative NanoSpark™ STEM-T Soluble T Cell Activator exhibited a remarkable 110-fold expansion by Day 10, with an industry-leading enrichment of TSCM at a final concentration of 40% and 90% for CD4+ and CD8+ subpopulations, respectively (Figure 1).
IL-7/IL-15 is applied to cell culture T cell expansion in a nearly identical format to the traditional addition of IL-2. It is recommended to follow the IL-2 protocol, but instead of adding 20 ng/mL, add IL-7/IL-15 cytokine supplement combination to the culture media at a final concentration of 10 ng/mL for each.
Nanotein Technology’s pioneering product, NanoSpark™ STEM-T Soluble T Cell Activator, represents a substantial advancement in adoptive cancer therapy. This innovation effectively addresses a critical challenge by leveraging a protein-based nanoparticle technology that seamlessly complements the action of IL-7/IL-15 cytokines.
TSCM cells possess the remarkable capacity for self-renewal and differentiation into diverse T cell subsets, ensuring their enduring presence within the patient’s body. NanoSpark™ STEM-T substantially augments this inherent potential, increasing the reservoir of TSCM cells available for therapeutic infusion.
The innovative NanoSpark™ platform offers a streamlined, highly efficient, and scientifically validated method for enhancing CAR-T and CAR-NK cells. It continues to catalyze future developments in cancer therapy, establishing itself as an invaluable asset for both researchers and patients.
Contact Nanotein today for further insights into this transformative technological breakthrough.
Subscribe to Our Newsletter
